Neuronoff

Neuronoff is pioneering a novel approach to peripheral neuromodulation with its Injectrode platform, a minimally invasive, injectable electrode designed to replace repeat drug injections for chronic pain. The company aims to lower the barriers to neuromodulation by enabling device placement and removal in a typical 20-minute clinic visit, positioning it as an earlier treatment option rather than a last resort. With over 52 million US adults suffering from chronic pain and a clear clinical need for drug-free, practical therapies, Neuronoff's technology targets a significant market gap. The platform has demonstrated multi-site IPG compatibility, suggesting potential expansion beyond its initial pain indication.

The Injectrode platform: a minimally invasive, injectable, and reversible electrode designed for percutaneous placement via an 18-gauge needle to deliver peripheral neuromodulation signals from an external pulse generator (EPG). It is compatible with multiple implantable pulse generator (IPG) systems.

Neuronoff competes indirectly with pharmaceutical pain therapies (opioids, NSAIDs) and direct injection therapies (corticosteroids). In neuromodulation, it competes with traditional, surgically implanted Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) systems from companies like Abbott, Boston Scientific, Medtronic, and Nevro. Its key differentiation is minimal invasiveness, reversibility, and clinic-based placement versus surgical implantation.